Warning Claim, Punitives Survive Dismissal In Invokana Ketoacidosis Case

(August 3, 2016, 12:49 PM EDT) -- ROME, Ga. — A Georgia federal judge on July 11 dismissed most claims by a plaintiff that the diabetes drug Invokana caused her diabetic ketoacidosis but said her failure-to-warn claims survive (Paula Brizil v. Janssen Research & Development LLC, et al., No. 15-204, N.D. Ga., Rome Div.; 2016 U.S. Dist. LEXIS 93528).

(Opinion available. Document #28-160804-015Z.)

Invokana is a diabetes drug of the sodium glucose co-transporter 2 (SGLT2) inhibitor class. It is prescribed to patients with type 2 diabetes to help control their blood glucose....
To view the full article, register now.